# Georgina V. Long

Source: https://onco.cc/people/georgina-long/  
OnCo record `georgina-long` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease.

## Summary

Georgina Long (Melanoma Institute Australia) led COMBI-d and COMBI-AD, the trials establishing dabrafenib plus trametinib in metastatic and adjuvant BRAF-mutant melanoma, and co-led NADINA, which showed neoadjuvant nivolumab plus ipilimumab beats adjuvant nivolumab in stage III melanoma and is changing the sequence of surgery and immunotherapy. She also led the ABC trial of immunotherapy for melanoma brain metastases and was 2024 Australian of the Year with Richard Scolyer.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; neoadjuvant; australia
- Role: Co-Medical Director, Melanoma Institute Australia; Chair of Melanoma Medical Oncology and Translational Research, University of Sydney
- Specialisms: Melanoma; Neoadjuvant immunotherapy; BRAF/MEK targeted therapy; Brain metastases

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Georgina_Long
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Long%20GV%5BAuthor%5D%20melanoma

## Connected records

- cancers: [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Stage III melanoma (after surgery)](https://onco.cc/cancers/stage-iii-melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BRAF](https://onco.cc/targets/braf/), [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Melanoma Institute Australia](https://onco.cc/institutions/melanoma-institute-australia/)
- trials: [COMBI-AD](https://onco.cc/trials/combi-ad/), [COMBI-d](https://onco.cc/trials/combi-d/), [NADINA](https://onco.cc/trials/nadina/)
- key papers: [NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma](https://onco.cc/key-papers/paper-nadina-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/georgina-long.json